ELISPOT analysis of a new CTL based DNA vaccine for HIV-1 using GM-CSF in DNA prime/peptide boost strategy: GM-CSF induced long-lived memory responses

Immunology Letters

Volumn 140, Issue 1-2, 2011, Pages 14-20

  Mahdavi, Mehdi ^a,b   Ebtekar, Massoumeh ^a   Khorram Khorshid, Hamid Reza ^c   Azadmanesh, Kayhan ^b   Hartoonian, Christine ^d   Hassan, Zuhair Mohammad ^a  

^a TARBIAT MODARES UNIVERSITY   (Iran)

^b PASTEUR INSTITUTE OF IRAN   (Iran)

^c UNIVERSITY OF SOCIAL WELFARE AND REHABILITATION SCIENCES   (Iran)

^d TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

DNA vaccine; ELISPOT; GM CSF; HIV 1 P24 Nef; Long lived immunity

Indexed keywords

DNA VACCINE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; INTERLEUKIN 4;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL ACTIVITY; CELL PROLIFERATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; GENETIC IMMUNIZATION; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGENICITY; LYMPHOCYTE FUNCTION; MEMORY T LYMPHOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ADJUVANTS, IMMUNOLOGIC; AIDS VACCINES; ANIMALS; CELLS, CULTURED; CYTOTOXICITY, IMMUNOLOGIC; ENZYME-LINKED IMMUNOSPOT ASSAY; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HIV CORE PROTEIN P24; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOLOGIC MEMORY; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; NEF GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; PEPTIDE FRAGMENTS; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES, CYTOTOXIC; VACCINES, DNA;

EID: 80051786697     PISSN: 01652478     EISSN: 18790542     Source Type: Journal    
DOI: 10.1016/j.imlet.2011.05.005     Document Type: Article

References (40)

1. Manickan E., Karem K.L., Rouse B.T. DNA vaccines - a modern gimmick or a boon to vaccinology?. Crit Rev Immunol 1997, 17:139-154.
2. Davis H.L., McCluskie M.J. DNA vaccines for viral diseases. Microbes Infect 1999, 1:7-21.
3. *. Annu Rev Immunol 2000, 18:927-974.
4. Xu R., Megati S., Roopchand V., Luckay A., Masood A., Garcia-Hand D., et al. Comparative ability of various plasmid-based cytokines and chemokines to adjuvant the activity of HIV plasmid DNA vaccines. Vaccine 2008, 26(37):4819-4829.
5. Dzierzbicka K., Kolodziejczyk A.M. Adjuvants - essential components of new generation vaccines. Postep Biochem 2006, 52:204-211.
6. Spearman P., Kalams S., Elizaga M., Metch B., Chiu Y.L., Allen M., et al. Safety and immunogenicity of a CTL multiepitope peptide vaccine for HIV with or without GM-CSF in a phase I trial. Vaccine 2009, 27:243-249.
7. Boyer J.D., Chattergoon M.A., Ugen K.E., Shah A., Bennett M., Cohen A., et al. Enhancement of cellular immune response in HIV-1 seropositive individuals: a DNA-based trial. Clin Immunol 1999, 90:100-107.
8. Kutzler M.A., Weiner D.B. Developing DNA vaccines that call to dendritic cells. J Clin Invest 2004, 114:1241-1244.
9. Dumont A.R., Kalfayan L.H., Sekaly R.P. Modulation of immune responses - strategies for optimising vaccines. Expert Opin Biol Ther 2004, 4:627-630.
10. Lori F., Weiner D.B., Calarota S.A., Kelly L.M., Lisziewicz J. Cytokine-adjuvanted HIV-DNA vaccination strategies. Springer Semin Immunopathol 2006, 28:231-238.
11. Forni G., Boggio K. Cytokine gene-engineered vaccines. Curr Opin Mol Ther 1999, 1:34-38.
12. Sasaki S., Tsuji T., Asakura Y., Fukushima J., Okuda K. The search for a potent DNA vaccine against AIDS: the enhancement of immunogenicity by chemical and genetic adjuvants. Anticancer Res 1998, 18:3907-3915.
13. Ramsay A.J., Ramshaw I.A. Cytokine enhancement of immune responses important for immunocontraception. Reprod Fertil Dev 1997, 9:91-97.
14. Okada E., Sasaki S., Ishii N., Aoki I., Yasuda T., Nishioka K., et al. Intranasal immunization of a DNA vaccine with IL-12- and granulocyte-macrophage colony-stimulating factor (GM-CSF)-expressing plasmids in liposomes induces strong mucosal and cell-mediated immune responses against HIV-1 antigens. J Immunol 1997, 159:3638-3647.
15. Abaitua F., Rodriguez J.R., Garzon A., Rodriguez D., Esteban M. Improving recombinant MVA immune responses: potentiation of the immune responses to HIV-1 with MVA and DNA vectors expressing Env and the cytokines IL-12 and IFN-gamma. Virus Res 2006, 116:11-20.
16. Kim J.J., Trivedi N.N., Nottingham L.K., Morrison L., Tsai A., Hu Y., et al. Modulation of amplitude and direction of in vivo immune responses by co-administration of cytokine gene expression cassettes with DNA immunogens. Eur J Immunol 1998, 28:1089-1103.
17. Pan C.H., Chen H.W., Tao M.H. Modulation of immune responses to DNA vaccines by codelivery of cytokine genes. J Formos Med Assoc 1999, 98:722-729.
18. Villinger F. Cytokines as clinical adjuvants: how far are we?. Expert Rev Vaccines 2003, 2:317-326.
19. Singh M., Srivastava I. Advances in vaccine adjuvants for infectious diseases. Curr HIV Res 2003, 1:309-320.
20. Frauenschuh A., DeVico A.L., Lim S.P., Gallo R.C., Garzino-Demo A. Differential polarization of immune responses by co-administration of antigens with chemokines. Vaccine 2004, 23:546-554.
21. Haddad D., Ramprakash J., Sedegah M., Charoenvit Y., Baumgartner R., Kumar S., et al. Plasmid vaccine expressing granulocyte-macrophage colony-stimulating factor attracts infiltrates including immature dendritic cells into injected muscles. J Immunol 2000, 165:3772-3781.
22. Kusakabe K., Xin K.Q., Katoh H., Sumino K., Hagiwara E., Kawamoto S., et al. The timing of GM-CSF expression plasmid administration influences the Th1/Th2 response induced by an HIV-1-specific DNA vaccine. J Immunol 2000, 164:3102-3111.
23. Barouch D.H., Santra S., Tenner-Racz K., Racz P., Kuroda M.J., Schmitz J.E., et al. Potent CD4+ T cell responses elicited by a bicistronic HIV-1 DNA vaccine expressing gp120 and GM-CSF. J Immunol 2002, 168:562-568.
24. Robinson H.L., Montefiori D.C., Villinger F., Robinson J.E., Sharma S., Wyatt L.S., et al. Studies on GM-CSF DNA as an adjuvant for neutralizing Ab elicited by a DNA/MVA immunodeficiency virus vaccine. Virology 2006, 352:285-294.
25. Song R., Liu S., Adams R.J., Leong K.W. Enhancing efficacy of HIV gag DNA vaccine by local delivery of GM-CSF in murine and macaque models. J Interferon Cytokine Res 2006, 26:380-389.
26. Qiu J.T., Chang T.C., Lin C.T., Chen Y.M., Li F.Q., Soong Y.K., et al. Novel codon-optimized GM-CSF gene as an adjuvant to enhance the immunity of a DNA vaccine against HIV-1 Gag. Vaccine 2007, 25:253-263.
27. Mahdavi M., Ebtekar M., Mahboudi F., Khorram Khorshid H., Rahbarizadeh F., Azadmanesh K., et al. Immunogenicity of a new HIV-1 DNA construct in a BALB/c mouse model. Iran J Immunol 2009, 6:163-173.
28. Anderson M.J., Shafer-Weaver K., Greenberg N.M., Hurwitz A.A. Tolerization of tumor-specific T cells despite efficient initial priming in a primary murine model of prostate cancer. J Immunol 2007, 178:1268-1276.
29. Lisziewicz J., Calarota S.A., Lori F. The potential of topical DNA vaccines adjuvanted by cytokines. Expert Opin Biol Ther 2007, 7:1563-1574.
30. Kim J.J., Yang J.S., Lee D.J., Wilson D.M., Nottingham L.K., Morrison L., et al. Macrophage colony-stimulating factor can modulate immune responses and attract dendritic cells in vivo. Hum Gene Ther 2000, 11:305-321.
31. McKay P.F., Barouch D.H., Santra S., Sumida S.M., Jackson S.S., Gorgone D.A., et al. Recruitment of different subsets of antigen-presenting cells selectively modulates DNA vaccine-elicited CD4+ and CD8+ T lymphocyte responses. Eur J Immunol 2004, 34:1011-1020.
32. Lewis J.D., Sullivan L.A., Byrne J.A., de Riese W., Bright R.K. Memory and cellular immunity induced by a DNA vaccine encoding self antigen TPD52 administered with soluble GM-CSF. Cancer Immunol Immunother 2009, 58:1337-1349.
33. Hartoonian C., Ebtekar M., Soleimanjahi H., Karami A., Mahdavi M., Rastgoo N., et al. Effect of immunological adjuvants: GM-CSF (granulocyte-monocyte colony stimulating factor) and IL-23 (interleukin-23) on immune responses generated against hepatitis C virus core DNA vaccine. Cytokine 2009, 46:43-50.
34. Jamali A., Mahdavi M., Hassan Z.M., Sabahi F., Farsani M.J., Bamdad T., et al. A novel adjuvant, the general opioid antagonist naloxone, elicits a robust cellular immune response for a DNA vaccine. Int Immunol 2009, 21:217-225.
35. Mahdavi M., Ebtekar M., Azadmanesh K., Khorramkhorshid H.R., Rahbarizadeh F., Yazdi M.H., et al. HIV-1 Gag p24-Nef fusion peptide induces cellular and humoral immune response in a mouse model. Acta Virol 2010, 54:131-136.
36. Moore A.C., Kong W.P., Chakrabarti B.K., Nabel G.J. Effects of antigen and genetic adjuvants on immune responses to human immunodeficiency virus DNA vaccines in mice. J Virol 2002, 76:243-250.
37. Hueman M.T., Stojadinovic A., Storrer C.E., Dehqanzada Z.A., Gurney J.M., Shriver C.D., et al. Analysis of naive and memory CD4 and CD8 T cell populations in breast cancer patients receiving a HER2/neu peptide (E75) and GM-CSF vaccine. Cancer Immunol Immunother 2007, 56:135-146.
38. Stambas J., Brown S.A., Gutierrez A., Sealy R., Yue W., Jones B., et al. Long lived multi-isotype anti-HIV antibody responses following a prime-double boost immunization strategy. Vaccine 2005, 23:2454-2464.
39. Manz R.A., Arce S., Cassese G., Hauser A.E., Hiepe F., Radbruch A. Humoral immunity and long-lived plasma cells. Curr Opin Immunol 2002, 14:517-521.
40. Neely G.G., Robbins S.M., Amankwah E.K., Epelman S., Wong H., Spurrell J.C., et al. Lipopolysaccharide-stimulated or granulocyte-macrophage colony-stimulating factor-stimulated monocytes rapidly express biologically active IL-15 on their cell surface independent of new protein synthesis. J Immunol 2001, 167:5011-5017.